東京大学 · 医学
Kotaro Sugawara教授の研究室は、食道がんや胃がんをはじめとする消化器がんの治療戦略に焦点を当てており、特にオナコリックウイルス療法や免疫チェックポイント阻害剤を用いたがん免疫療法の効果を解明しています。また、炎症マーカーや栄養状態を指標とする予後予測モデルの構築や、再発・残存がんに対する救命的手術の意義についても臨床的・疫学的アプローチで研究を進めています。がん治療における個別化医療の実現に向け、バイオマーカーと治療戦略の統合的アプローチを追求しています。
Figures are computed from collected data and may differ slightly.
Oncolytic virus therapy can increase the immunogenicity of tumors and remodel the immunosuppressive tumor microenvironment, leading to an increased antitumor response to immune-checkpoint inhibitors. Here, we investigated the therapeutic potential of G47Δ, a third-generation oncolytic herpes simplex virus type 1, in combination with immune-checkpoint inhibitors using various syngeneic murine subcutaneous tumor models. Intratumoral inoculations with G47Δ and systemic anti-cytotoxic T-lymphocyte-a
GNRI is useful for predicting survival and oncological outcomes in GC patients.
Various inflammatory or nutritional markers, especially those derived from CRP, are useful for predicting survival outcomes of ESCC patients. The predictive capabilities of these indices were augmented when used in combination with pStage.
Salvage esophagectomy (SALV) is potentially beneficial for patients with residual or relapsed esophageal carcinoma after definitive chemoradiotherapy (dCRT), although preoperatively identifying good candidates for SALV remains difficult. We investigated the prognostic impacts of inflammatory and nutritional status in patients undergoing SALV after dCRT. Forty-seven SALV patients were retrospectively reviewed, of whom 46 (98%) had squamous cell carcinoma and 1 (2%) adenocarcinoma. Possible progno
The survival outcomes of patients with relapsed EC remain poor. Surgical treatments could provide survival benefits for patients with recurrent EC, especially for patients with OM.
Open papers in the app to read, cite, and organize with AI.
